BII TRANS TECH (01522) Appoints Li Yi as Non-Executive Director
BII TRANS TECH (01522) announces that, with effect from 22 October 2026, Mr. Ren Yuhang has resigned as a non-executive director and ceased to serve as the chairman of the board, the chairman of the nomination committee and the ESG committee, and a member of the remuneration committee; Mr. Wang Daomin has resigned as a non-executive director; Mr. Li Yi has been appointed as a non-executive director; Mr. Liu Yu has been re-designated from a member of the ESG committee to the chairman of the ESG committee, and has been appointed as a member of each of the nomination committee and the remuneration committee; and Ms. Wu Ying'en has been re-designated from a member of the nomination committee to the chairman of the nomination committee, and has been appointed as a member of the ESG committee.
BII TRANS TECH (01522) announces that, with effect from October 22, 2026, Mr. Ren Yuhang has resigned as a non-executive director and ceased to serve as chairman of the board, chairman of the nomination committee and the ESG committee, and a member of the remuneration committee; Mr. Wang Daomin has resigned as a non-executive director; Mr. Li Yi has been appointed as a non-executive director; Mr. Liu Yu has been re-designated from a member of the ESG committee to chairman of the ESG committee, and has been appointed as a member of each of the nomination committee and the remuneration committee; and Ms. Wu Ying'en has been re-designated from a member of the nomination committee to chairman of the nomination committee, and has been appointed as a member of the ESG committee.
Related Articles
IPO Insight | Mufemilast commercialization begins, Hemei Pharmaceutical's 18A listing enters countdown
TRANSTHERA-B (02617) repurchased 5,500 shares on October 22 at a cost of approximately HK$47,200.
Xinhua Winshare Publishing & Media (00811) will distribute an interim dividend of HK$0.198334 per share on December 22.
IPO Insight | Mufemilast commercialization begins, Hemei Pharmaceutical's 18A listing enters countdown
TRANSTHERA-B (02617) repurchased 5,500 shares on October 22 at a cost of approximately HK$47,200.
Xinhua Winshare Publishing & Media (00811) will distribute an interim dividend of HK$0.198334 per share on December 22.
